Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kate Therapeutics Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, MARVICH, MARIA. The prosecution activity is concentrated in 1 distinct art unit. MARVICH, MARIA is the busiest examiner for the company, as this examiner is responsible for 1 pending action. This 1 pending action represents the entirety of the company's current interaction with the patent office in this technology area. The use of 1 distinct art unit suggests a very specific technical focus for the application.
Because there is 1 distinct examiner, the outcome of the prosecution depends on the individual evaluation of MARVICH, MARIA. The company's strategy in the Biotechnology & Pharmaceuticals sector currently involves 1 pending office action. This 1 pending office action is being reviewed in 1 distinct art unit. MARVICH, MARIA, the busiest examiner, is handling 1 pending action. The focus on 1 distinct examiner and 1 distinct art unit indicates a streamlined prosecution process for this specific matter. For a patent practitioner, this concentration means the legal strategy can be highly tailored to the specific technical standards of 1 distinct art unit and the preferences of 1 distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19406703 | LIVER DETARGETED CAPSIDS | MARVICH, MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19406703 | LIVER DETARGETED CAPSIDS | MARVICH, MARIA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19406703 | LIVER DETARGETED CAPSIDS | MARVICH, MARIA | 1634 | §103§112 | Non-Final OA | — | Pending | Dec 02, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial